ROKIT Healthcare’s bioprinting-based diabetic foot treatment kit registered as a U.S. FDA medical device
ROKIT Healthcare has completed registration of its Dr. INVIVO-based diabetic foot treatment with the U.S. FDA and has successfully completed clinical studies in the U.S.
Since 2019, the company has conducted clinical studies in India, Korea and Turkey, and based on the most recent study results in the U.S., the treatment has shown promising results in all of the study patients with no side effects.
The company reported that the study subjects were patients of chronic diabetic foot ulcer with an average of 64.4 years of age, 15 years of diabetes duration, and obesity in 90% of the patients.
The principal investigator behind the study is Dr. David G. Armstrong, PhD, DPM, who is Professor of Clinical Surgery at University of Southern California and has produced more than 510 peer-reviewed research papers in scholarly medical journals and 90 book chapters with expertise in the treatment and clinical care of the diabetic foot. Dr. Armstrong is past Chair of Scientific Sessions for the American Diabetes Association’s Foot Care Council and the founder and co-chair of the International Diabetic Foot Conference, the largest annual international symposium on the diabetic foot in the world.
“There is no existing method that resolves chronic diabetic foot ulcers by way of true regenerative medicine, especially for those ulcers that failed to close for many months,” said an official of ROKIT Healthcare. “We have seen our bioprinting-based diabetic foot ulcer treatment offer hope for patients who recovered and got back on their feet within just a few weeks after one procedure, making daily life possible again.
“The clinical study results have demonstrated that ROKIT Healthcare’s diabetic foot ulcer treatment kit can effectively regenerate skin of diabetic foot affected areas regardless of various variables such as race, age, and underlying disease. I can take one more step,” he said.
ROKIT Healthcare’s diabetic foot ulcer treatment, which consists of the printer Dr. INVIVO DFU and patient-specific autologous solution extraction kits, uses 3D scanning and AI-based interpretation of patient wounds to create customized skin regeneration patches.
“Given the FDA medical device registration and several successful global studies yielding promising results, we are proud to be leading a meaningful work of saving human lives with cutting-edge regenerative medicine technologies,” said Seok-Hwan You, CEO of ROKIT Healthcare. “I look forward to contributing to the advancement of chronic ulcer treatment methods and significantly improving the quality of life for patients.”
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
APWORKS Expands Scalmalloy 3D Printing with Farsoon and CNPC Partnerships
In the lead up to Formnext 2024, Airbus subsidiary APWORKS has teamed up with Farsoon Technologies and CNPC Powder to expand the production and application of Scalmalloy, APWORKS’ high-strength, corrosion-resistant...
3D Printer OEM Axtra3D Raises Nearly $10M in Series A
Axtra3D, an original equipment manufacturer (OEM) of 3D printers leveraging the company’s patented Hybrid Photosynthesis (HPS) technology, has received another $4.5 million in Series A financing, bringing its total Series...
Caracol AM to Launch its First Metal 3D Printer at Formnext 2024
Caracol AM, a US-Italian original equipment manufacturer (OEM) of large-format additive manufacturing (AM) systems, has announced the launch of the company’s first metal printer, Vipra AM. A directed energy deposition...
ADDIMETAL to Debut First French Metal Binder Jetting 3D Printer at Formnext 2024
ADDIMETAL, a French original equipment manufacturer (OEM) of additive manufacturing (AM) hardware, will debut its first product, the K2-2 metal binder jetting (MBJ) printer, at Formnext 2024 in Frankfurt, Germany...